SPAC deals are creeping back into the mainstream, with Liminatus Pharma and Iris Acquisition Corp. becoming the latest in the biotech sphere to test the waters.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,